The scale of the problem motivating such research is hard to overstate. Neurodegenerative disorders are defined by the progressive loss of neurons, and they remain a leading global health concern precisely because they are so complex. Age is the single greatest risk factor, and as populations around the world grow older, the incidence of dementia and movement disorders continues to climb. Decades of single-target drug development have repeatedly disappointed, largely because these diseases do not arise from one defect but from overlapping failures: oxidative stress that damages cellular machinery, chronic inflammation that smolders in brain tissue, mitochondria that falter in their energy production, and neurotransmitter systems that fall out of balance. Compounds that can act on several of these fronts simultaneously, as apigenin appears to do, are therefore attracting attention as plausible multi-target therapeutics.

The first line of defense the review describes is antioxidant. Neurons are extraordinarily vulnerable to reactive oxygen species, the unstable molecules generated during normal metabolism that become destructive when produced in excess. Apigenin works on two levels here. Directly, it scavenges free radicals, neutralizing them before they can attack lipids, proteins, and DNA. Indirectly, and arguably more importantly, it activates the body’s own antioxidant arsenal by engaging the Nrf2 signaling pathway, a master regulator that switches on suites of protective genes when the cell senses oxidative threat. By strengthening this endogenous system rather than simply donating electrons to radicals, apigenin mimics the kind of layered defense that evolved cells already use, amplifying it at the moment of need.

Inflammation is the second pillar of apigenin’s neuroprotective profile. In the brain, the resident immune cells known as microglia normally patrol for damage and infection, but in neurodegenerative disease they become chronically activated, releasing pro-inflammatory cytokines that injure the very neurons they are meant to protect. Apigenin reins in this process by inhibiting two central inflammatory signaling cascades, NF-κB and MAPK, which act as molecular switches controlling cytokine production. Experimental studies cited in the review show that the compound suppresses microglial activation in models of Alzheimer’s disease and chronic neuroinflammation, and in some cases preserves spatial memory that inflammation would otherwise erode. Work on astrocytes, the supportive glial cells that also participate in inflammatory responses, points to the same conclusion: apigenin dampens cytokine output by targeting MAPK, STAT3, and NF-κB signaling simultaneously.

Energy failure is another hallmark of the dying neuron, and here the review highlights apigenin’s effects on mitochondria and on programmed cell death. When mitochondria malfunction, they release signals that tip cells toward apoptosis, a form of cellular suicide executed by caspase enzymes and governed by the Bcl-2 family of proteins. Apigenin modulates this balance, favoring survival by regulating Bcl-2 family members and restraining caspase activity. Beyond simply blocking the death pathway, the compound appears to actively restore mitochondrial health by promoting mitophagy, the controlled recycling of damaged mitochondria. In a mouse model of lipopolysaccharide-induced neurotoxicity, apigenin’s benefits were traced to the SIRT3/PINK1/Parkin pathway, a well-characterized route for identifying and clearing defective mitochondria before they poison the cell.

The review also emphasizes apigenin’s role in autophagy more broadly, the cellular housekeeping system that clears misfolded and aggregated proteins. Protein aggregation is the defining pathology of several neurodegenerative diseases: amyloid-beta plaques in Alzheimer’s disease, and alpha-synuclein clumps in Parkinson’s disease. Recent research shows that apigenin enhances Nrf2-induced chaperone-mediated autophagy, a selective clearance mechanism, and thereby mitigates alpha-synuclein pathology with direct implications for Parkinson’s therapy. In cellular and animal models of Alzheimer’s disease, the flavonoid has been shown to inhibit amyloid-beta aggregation while also activating TrkB signaling, the receptor pathway through which brain-derived neurotrophic factor supports neuronal survival and synaptic plasticity. Notably, one 2023 study found that apigenin can physically bind BDNF and potentiate its neurotrophic activity, suggesting the molecule does not merely mimic growth factors but may amplify the ones already present.

Vascular and barrier protection round out the compound’s portfolio. The blood-brain barrier, the tightly sealed lining of blood vessels in the brain, breaks down in many neurological conditions, admitting immune cells and toxins that accelerate neural damage. Apigenin has been shown to protect barrier integrity in models of subarachnoid hemorrhage by inhibiting TLR4-mediated inflammation, and systems pharmacology analyses point to mechanisms by which it counters barrier disruption in ischemic stroke. The compound also influences neurotransmission itself. In the rat hippocampus, apigenin inhibits excessive glutamate release, taming the excitotoxicity that kills neurons during stroke and in chronic disease. It acts as a ligand for GABA-A receptors, the principal inhibitory channels in the brain, modulates cholinergic signaling relevant to memory through acetylcholinesterase inhibition, and interacts with monoaminergic systems, including serotonergic and catecholaminergic pathways implicated in depression, as well as monoamine oxidase enzymes targeted by classic antidepressant and anti-Parkinsonian drugs.

For all this promise, the review is candid about the obstacles standing between laboratory findings and the clinic. The central problem is bioavailability. Apigenin is poorly absorbed, extensively metabolized by sulfation and glucuronidation in the liver and intestine, and rapidly cleared, so the concentrations that produce striking effects in cell cultures are difficult to achieve in human blood and even harder to reach inside the brain. Human pharmacokinetic studies, including work on apiin-rich parsley and on apigenin glycosides in healthy adults, confirm that systemic exposure to the parent compound is limited. There are safety considerations as well: high-dose studies in mice have reported hepatotoxicity, subacute exposure alters liver protein synthesis, and apigenin can interfere with the pharmacokinetics of other drugs such as venlafaxine through interactions with transporters and metabolic enzymes, raising herb-drug interaction concerns for any future therapeutic use.

Scientists are attacking the delivery problem from several directions. Nanoparticle formulations, including targeted nanoparticles that enhanced apigenin delivery in a model of secondary brain injury after intracerebral hemorrhage, have improved brain exposure. Injectable nanosized delivery systems, self-nanoemulsifying drug delivery systems that boosted oral absorption, and cleavable amino acid conjugates that ferry the molecule across the blood-brain barrier all represent engineering solutions to an old pharmacological challenge. Epidemiology offers a complementary angle: large cohort studies, including the Danish Diet, Cancer and Health Cohort and a 2025 analysis in Nature Food, link higher and more diverse dietary flavonoid intake with lower all-cause mortality and reduced risk of major chronic diseases, suggesting that regular dietary exposure may confer subtle but meaningful protection even at doses far below those used in animal experiments.

The review’s overall verdict is measured but hopeful. Apigenin is not a cure, and no human clinical trial has yet demonstrated that it can slow Alzheimer’s, Parkinson’s, or Huntington’s disease; indeed, the authors note that clinical application remains limited precisely because of bioavailability challenges and the scarcity of human studies. Registered trials exploring related botanical approaches, such as the evaluation of saffron and chamomile in Parkinson’s disease, hint at where the field may head next. What the accumulated evidence does establish is that a single dietary molecule can simultaneously engage oxidative stress, neuroinflammation, mitochondrial dysfunction, protein aggregation, barrier failure, and neurotransmitter imbalance, the very hallmarks that have made neurodegeneration so resistant to single-target drugs. Turning that broad pharmacological profile into a safe, brain-penetrant therapy will require better formulations and rigorous clinical testing, but the review makes a compelling case that one of the most promising leads in neuroprotection may be growing in the garden rather than waiting in the chemistry lab.

Subject of Research: Neuroprotective mechanisms of the dietary flavonoid apigenin in neurodegenerative diseases

Article Title: Therapeutic potential of apigenin in neurodegenerative diseases and brain health

Article References: Aldiqs, M., Aliev, M., Gajjar, T. B., Senapati, J. N., Alhasso, B., Urazbaeva, D., Aminqulov, S., & Mishra, M. K. (2026). Therapeutic potential of apigenin in neurodegenerative diseases and brain health. Molecular Biology Reports, 53(1), Article 1540. https://doi.org/10.1007/s11033-026-12703-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12703-z

Keywords: apigenin, flavonoid, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, oxidative stress, neuroinflammation, mitochondrial dysfunction, Nrf2, NF-κB, blood-brain barrier, bioavailability